Loading…
iSpecimen Inc. is projected to decline to $2.33 by 2027, a -7% move from its current price of $2.50. ISPC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.39 | $2.50 | $2.62 | +0.09% |
| Jul 14 | $2.35 | $2.50 | $2.67 | +0.18% |
| Jul 15 | $2.32 | $2.51 | $2.71 | +0.28% |
| Jul 16 | $2.30 | $2.51 | $2.74 | +0.37% |
| Jul 17 | $2.27 | $2.51 | $2.77 | +0.46% |
| Jul 18 | $2.26 | $2.51 | $2.80 | +0.55% |
| Jul 19 | $2.24 | $2.52 | $2.83 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.24 | $2.52 | $2.83 | +0.64% |
| Week 2 | $2.15 | $2.53 | $2.99 | +1.29% |
| Week 3 | $2.08 | $2.55 | $3.12 | +1.94% |
| Week 4 | $2.03 | $2.56 | $3.24 | +2.60% |
| Week 5 | $1.99 | $2.58 | $3.35 | +3.26% |
| Week 6 | $1.95 | $2.60 | $3.46 | +3.92% |
| Week 7 | $1.92 | $2.61 | $3.56 | +4.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.
iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
ISPC is a healthcare stock trading at $2.40 in current activity, with a market cap of $3.45M and a rank of 5413. The company operates within the Healthcare category and provides a marketplace for biospecimens to researchers and institutions across multiple regions.
Forecasts depict a path of evolving value with year-by-year ranges. For 2026, min $2.40, avg $2.40, max $3.20; by 2029, avg $3.36 with a 39.9% ROI; by 2030, avg $3.14 and a 30.9% ROI; through 2050, avg $8.45, max $18.56 with a 252.1% ROI, indicating substantial upside potential in the long run. The max price in 2050 is $18.56 and the overall sentiment shifts to bullish in several later years.
The current price sits near a multi-year framework that suggests gradual gains with notable upside toward the end of the forecast horizon, though some years show flatter or negative momentum. Investors should regard these figures as estimates and not guarantees, with sentiment transitioning from neutral to bullish in key long-horizon years.
A major floor 33.6% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
The nearest ceiling, 33.6% above — a clean break opens room to run.
A major ceiling 354.4% above — clearing it would confirm fresh momentum.
Key ISPC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ISPC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.46 | Buy | $2.50 | Buy |
| MA 10 | $2.58 | Sell | $2.54 | Sell |
| MA 20 | $2.61 | Sell | $2.69 | Sell |
| MA 50 | $3.44 | Sell | $3.65 | Sell |
| MA 100 | $5.57 | Sell | $6.76 | Sell |
| MA 200 | $14.50 | Sell | $19.21 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.67 | Neutral |
| Stoch RSI (14) | 87.04 | Sell |
| CCI (20) | -71.22 | Neutral |
| Williams %R (14) | -58.00 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | -1.57 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 42.00 | Neutral |
| TRIX (15) | -1.37 | Sell |
| Awesome (5,34) | -0.38 | Sell |
| Ultimate (7,14,28) | 42.38 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 2.37 | Buy |
| ADX (14) | 28.32 | Sell |
| ATR (14) | 0.13 | Info |
The near-term technical picture is NEUTRAL, with RSI14 at 30. The 50-day simple moving average sits at $3.59, while the 200-day simple moving average is at $15.38, indicating the longer-term average is well above the current price.
Price currently trades at a defined support level of $2.40 and faces resistance at $3.45. The 30-day trading range extends from $1.83 to $3.15, providing a baseline of recent volatility. These indicators together imply a cautious stance in the near term, with potential upside if the price can clear the $3.45 resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.29 | $2.50 | $3.36 | 0% | Neutral | |
| $1.75 | $2.33 | $3.34 | -7% | Neutral | |
| $1.81 | $2.54 | $3.84 | +1% | Neutral | |
| $2.43 | $3.54 | $5.60 | +42% | Bullish | |
| $2.21 | $3.33 | $5.46 | +33% | Bullish | |
| $1.92 | $3.00 | $5.06 | +20% | Neutral | |
| $1.96 | $3.17 | $5.50 | +27% | Bullish | |
| $1.72 | $2.86 | $5.08 | +14% | Neutral | |
| $1.80 | $3.09 | $5.61 | +23% | Bullish | |
| $2.19 | $3.86 | $7.16 | +55% | Bullish | |
| $1.93 | $3.91 | $7.89 | +56% | Bullish | |
| $4.02 | $8.93 | $20.31 | +257% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.29 | $2.50 | $2.98 | +0.00% |
| August 2026 | $2.16 | $2.59 | $3.22 | +3.52% |
| September 2026 | $2.24 | $2.72 | $3.44 | +5.02% |
| October 2026 | $2.13 | $2.61 | $3.35 | -3.97% |
| November 2026 | $2.03 | $2.51 | $3.26 | -3.89% |
| December 2026 | $2.05 | $2.56 | $3.36 | +1.85% |
Click any year to see its month-by-month ISPC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ISPC price prediction for 2026 points to an average of $2.50 (low $2.29, high $3.36) — a potential gain of 0% on today's $2.50. Price action looks broadly range-bound.
In 2027, ISPC is projected to trade between $1.75 and $3.34, averaging $2.33 — a potential decline of -7% from today's $2.50. That is -7% versus the projected 2026 average. A consolidation phase looks the most probable path here.
iSpecimen Inc.'s 2028 outlook centres on $2.54, within a $1.81 to $3.84 range. That is up +9% on the projected 2027 average. That marks a +1% change versus current levels. Price action looks broadly range-bound.
By 2029, ISPC could reach as high as $5.60, with a base case around $3.54 and support toward $2.43 — roughly +42% from $2.50. Buyers look set to stay in control over this stretch.
Expect ISPC to range from $2.21 to $5.46 through 2030. The $3.33 average target implies a +33% move from current prices. That is -6% versus the projected 2029 average. Momentum favours further upside here.
The ISPC price prediction for 2031 points to an average of $3.00 (low $1.92, high $5.06) — a potential gain of +20% on today's $2.50. A consolidation phase looks the most probable path here.
In 2032, ISPC is projected to trade between $1.96 and $5.50, averaging $3.17 — a potential gain of +27% from today's $2.50. That is up +6% on the projected 2031 average. Momentum favours further upside here.
iSpecimen Inc.'s 2033 outlook centres on $2.86, within a $1.72 to $5.08 range. That is -10% versus the projected 2032 average. That marks a +14% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, ISPC could reach as high as $5.61, with a base case around $3.09 and support toward $1.80 — roughly +23% from $2.50. Momentum favours further upside here.
Expect ISPC to range from $2.19 to $7.16 through 2035. The $3.86 average target implies a +55% move from current prices. That is up +25% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ISPC price prediction for 2040 points to an average of $3.91 (low $1.93, high $7.89) — a potential gain of +56% on today's $2.50. Momentum favours further upside here.
In 2050, ISPC is projected to trade between $4.02 and $20.31, averaging $8.93 — a potential gain of +257% from today's $2.50. That is up +128% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ISPC today (≈ 400 ISPC) could be worth
$3,570.79
+$2,570.79 (+257%) by 2050 · US Dollar
Based on the average projected ISPC price of $8.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ISPCwould be worth at today's price.
$1,000 invested in ISPC on Jul 10, 2025 (≈ 22.935781 ISPC) would be worth
$57.34
-$942.66 (-94.3%) today · 0.06× · US Dollar
Based on a ISPC entry price of $43.6 vs. today's $2.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.64 | $946.97 | -5.3% |
| 1 month ago | $2.68 | $932.84 | -6.7% |
| 3 months ago | $5.12 | $488.28 | -51.2% |
| 6 months ago | $12.4 | $201.61 | -79.8% |
| 1 year ago | $43.6 | $57.34 | -94.3% |
| All time (5.0y) ago | $5,288 | $0.47 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ISPC forecast.
Our base-case forecast reaches $5.00 around 2050.
Implied market cap at $5.00: $7.19M
The multi-year forecast shows a path of rising averages and growing upside, with 2029 averaging $3.36 (ROI 39.9%) and 2030 averaging $3.14 (ROI 30.9%), both labeled as neutral to bullish sentiment. The trajectory continues into 2032, 2034, and 2035 with growing confidence and higher average prices, including 2035 at an average of $3.70 (ROI 54.3%).
By 2040, the forecast projects an average price of $3.81 (ROI 58.7%) with bullish sentiment, and by 2050 an average of $8.45 (ROI 252.1%) and a bullish outlook, with the max reaching $18.56. These later years reflect substantial upside potential, supported by the long-horizon bullish sentiment, against a backdrop of earlier neutral readings.
These figures are estimates, not guarantees. They illustrate potential paths based on the provided inputs and should be weighed with consideration of the embedded risks and the long horizon over which the price may evolve.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.14, with a min of $2.12 and a max of $5.04, and a projected ROI of 30.9% with bullish sentiment.
The forecast shows a mix of years with positive returns (e.g., 2029 avg $3.36, ROI 39.9%; 2040 avg $3.81, ROI 58.7%; 2050 avg $8.45, ROI 252.1%) and at least one year with negative/soft momentum (2027 avg $2.24, ROI -6.5%). These are estimates, not guarantees.
The 2050 forecast maximum is $18.56, indicating a path where prices could exceed $10 in the upper tail of the distribution, but these are not guarantees and depend on future conditions.
The 30-day range is $1.83 to $3.15.
iSpecimen Inc. Community Discussion
0Share your iSpecimen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.